Imatinib prevents beta cell death in vitro but does not improve islet transplantation outcome

Aileen J. F. King, Lisa A. Griffiths, Shanta J. Persaud, Peter M. Jones, Simon L. Howell & Nils Welsh

To cite this article: Aileen J. F. King, Lisa A. Griffiths, Shanta J. Persaud, Peter M. Jones, Simon L. Howell & Nils Welsh (2016): Imatinib prevents beta cell death in vitro but does not improve islet transplantation outcome, Upsala Journal of Medical Sciences, DOI: 10.3109/03009734.2016.1151090

To link to this article: http://dx.doi.org/10.3109/03009734.2016.1151090

© 2016 The Author(s). Published by Taylor & Francis.

Published online: 08 Mar 2016.

Submit your article to this journal

Article views: 72

View related articles

View Crossmark data
Imatinib prevents beta cell death in vitro but does not improve islet transplantation outcome

Aileen J. F. King\textsuperscript{a}, Lisa A. Griffiths\textsuperscript{a}, Shanta J. Persaud\textsuperscript{a}, Peter M. Jones\textsuperscript{a}, Simon L. Howell\textsuperscript{a} and Nils Welsh\textsuperscript{b}

\textsuperscript{a}Diabetes Research Group, Division of Diabetes and Nutritional Sciences, King’s College London, Guy’s Campus, London SE1 1UL, United Kingdom; 
\textsuperscript{b}Department of Medical Cell Biology, Uppsala University, Biomedicum, Uppsala, Sweden

\textbf{Introduction}

Strategies to improve islet transplantation as a therapy for type 1 diabetes have been extensively studied by research groups across the world, including Uppsala University (1–16) and King’s College London (17–25). The advantages are apparent; improving islet transplantation outcome could not only bring benefits to individual patients but also widen the patient pool to which this life-changing treatment is available. Imatinib has previously been shown to protect beta cells from apoptosis in a variety of in vitro and in vivo models. The aim of this study was to investigate whether imatinib could be used to improve islet transplantation outcome.

\textbf{Methods}

Islets were isolated from C57Bl/6 mice and pre-cultured with imatinib prior to exposure to streptozotocin and cytokines in vitro. Cell viability and glucose-induced insulin secretion were measured. For transplantation experiments, islets were pre-cultured with imatinib for either 72 h or 24 h prior to transplantation into streptozotocin-diabetic C57Bl/6 mice. In one experimental series mice were also administered imatinib after islet transplantation.

\textbf{Results}

Imatinib partially protected islets from beta cell death in vitro. However, pre-culturing islets in imatinib or administering the drug to the mice in the days following islet transplantation did not improve blood glucose concentrations more than control-cultured islets.

\textbf{Conclusion}

Although imatinib protected against beta cell death from cytokines and streptozotocin in vitro, it did not significantly improve syngeneic islet transplantation outcome.

\textbf{Materials and methods}

\textbf{Animals}

All mice were 8–10-week-old males sourced from Harlan (Huntingdon, UK). Mice were housed in 12 h light/dark cycles and had access to pelleted food and water ad libitum. C57Bl/6 or ICR mice were used for islet isolation for in vivo and in vitro experiments, respectively. To induce diabetes, C57Bl/6 mice were injected with 180 mg/kg streptozotocin (Sigma-Aldrich, Poole, UK) 5–7 days prior to islet transplantation. Blood glucose concentrations were monitored using Accu-Chek blood glucose meter and strips (Accu-Chek Aviva, Roche Diagnostics, Burgess Hill, UK), and mice with blood glucose concentrations over 20 mM were considered diabetic. All animal experiments were ethically approved by our institution and were carried out under
Islet isolation

Islets were isolated using collagenase digestion and gradient purification as previously described. Briefly, mice were killed by cervical dislocation and the pancreatic duct was clamped at the ampulla of Vater. A volume of 2 mL of collagenase (Type XI, 1 mg/mL, Sigma-Aldrich) were injected into the pancreatic duct before removal of the distended pancreas and incubation for 10 min at 37°C. Islets were purified from the pancreatic digest using a Histopaque-1077 (Sigma-Aldrich) gradient. Islets were washed and subsequently cultured in RPMI 1640 (Sigma-Aldrich) supplemented with 10% foetal calf serum (FCS; Sigma-Aldrich), 2 mM L-glutamine, and antibiotics (100 units/mL penicillin + 100 ng/mL streptomycin; Sigma-Aldrich).

Cytokine treatment in vitro

Islets from ICR mice were pre-cultured for 24 h in the presence or absence of 10 μM imatinib (Selleckchem, Suffolk, UK) prior to the exposure of the islets to 50 U/mL IL-1β (PeproTech, London, UK), 1,000 U/mL TNF-α (PeproTech), and 1,000 U/mL IFN-γ (PeproTech) for 24 hours. Apoptosis in the islets was then measured by Caspase-Glo 3/7 (Promega, Southampton, UK), and viability was measured by Cell-titer Glo (Promega) which detects ATP.

Streptozotocin treatment in vitro

Islets from ICR mice were pre-cultured for 24 h in the presence or absence of 10 μM imatinib prior to the exposure of the islets to 1.5 mM streptozotocin in serum-free RPMI media containing 5.6 mM glucose. After 30 min the islets were washed and placed in normal culture conditions overnight (RPMI 1640 with 11.1 mM glucose and 10% FCS). Apoptosis in the islets was then measured by Caspase-Glo 3/7. Islet function was assessed by measuring glucose-induced insulin secretion.

Glucose-induced insulin secretion

Insulin secretion was measured as previously described in detail (18). Islets were pre-incubated for 2 h in RPMI media containing 2 mM glucose and 10% foetal calf serum. For each experiment, eight to ten groups of three islets were picked into 1.5 mL Eppendorf tubes containing a bicarbonate-buffered physiological salt solution, containing 2 mM CaCl₂ and 0.5 mg/mL BSA with 2 mM or 20 mM glucose. The islets were incubated at 37°C for 1 h at each glucose concentration. Supernatants were removed and frozen until insulin was measured by an in-house radioimmunoassay (42).

Islet transplantation

Donor islets were isolated from C57Bl/6 mice and pre-cultured in the presence or absence of 10 μM imatinib. A minimal mass of 200 islets were syngeneically implanted under the kidney capsule of streptozotocin-diabetic C57Bl/6 recipients. Briefly, animals were anaesthetized using isoflurane (1%–5% isoflurane, 95% oxygen). Buprenorphine, 30 μg/kg, was administered as an analgesic at the start of surgery. Once the animal was anaesthetized, an incision was made on the left flank. The kidney was externalized and an incision made in the kidney capsule. Islets were centrifuged into PE50 tubing (Becton Dickinson, Sparks, MD, USA), and a Hamilton syringe (Fisher, Pittsburg, PA, USA) was used to deliver the islets under the kidney capsule. Three series of transplantation experiments were carried out. In the first experimental series islets were pre-cultured for 3 days in the presence or absence of 10 μM imatinib, and in the second experimental series the islets were pre-cultured for 24 h in the presence or absence of 10 μM imatinib. In both cases the mice were monitored for 14 days. In the third experimental series, we focused on the immediate post-transplantation period. Islets were pre-cultured for 24 h in the presence or absence of 10 μM imatinib, and imatinib was also administered by gavage to the recipient mice (200 mg/kg) 1 h prior to transplantation and daily thereafter. The mice were killed, and the islet graft-bearing kidneys were removed to measure insulin content as previously described (20).

Statistics

Data were analysed using Sigmaplot (Systat Software Inc., Hounslow, UK). Two groups were compared using an unpaired t test, whereas three or more groups were analysed using a one-way ANOVA. Blood glucose data were analysed using two-way repeated measures (rm) ANOVA.

Results

Pre-treatment of islets with imatinib does not affect islet transplantation outcome

Pre-treatment of islets with imatinib for 3 days prior to transplantation did not affect islet transplantation outcome (Figure 3A). A similar pattern was seen when islets were
pre-treated with imatinib for 24 h prior to islet transplantation (Figure 3B).

**Pre-treatment of islets with imatinib combined with donor treatment transiently improved islet transplantation outcome in the immediate post-transplantation period**

In a third transplantation series we pre-treated the islets with imatinib for 24 h and also administered imatinib to the mice by gavage. In these animals, there was significantly reduced blood glucose concentrations in mice that received imatinib gavage combined with imatinib pre-treated islets on the first 2 days after implantation, but this effect was lost by day three (Figure 4A). Graft insulin content was not significantly different between the treatments (Figure 4B). Mice gavaged with imatinib that did not receive an islet graft remained overtly diabetic.

**Discussion**

We have shown that pre-treatment of islets with imatinib partially protected islets from both cytokine and streptozotocin-induced damage *in vitro*. This is in agreement with previous studies which have shown the ability of imatinib to inhibit apoptosis in various cell types (43,44) including insulin-producing cells (33,34,45). The mechanism may be dependent on c-Abl rather than c-Kit, which is an alternative target of imatinib (34,46). Pre-incubation of islets with imatinib is necessary to provide protection against streptozotocin, nitric oxide, and cytokines, which indicates a state of preconditioning (33). Exactly how imatinib promotes improved beta-cell survival is not clear, but it has been proposed that altered signalling via the JNK, ERK, PI3K, β-catenin, NF-κB, and PKCδ signalling pathways may alone, or in combinations, mediate the effects of imatinib (33–36,45,47,48). Of these pathways, the NF-κB and JNK pathways have been studied in relation to islet transplantation outcome. Although short-term exposure of islets to imatinib is associated with NF-κB activation, longer incubation periods as used in the current study reduce NF-κB activation in beta cells (36), leading to a lower sensitivity to cytokines. While this effect was seen in the *in vitro* experiments, this did not translate to improved islet transplantation outcomes in our minimal mass transplantation model in mice. The effects of NF-κB activation on islet transplantation outcome are...
ambiguous, with studies suggesting that acute inactivation may be beneficial (49–51), whereas chronic inactivation may be ineffective (52). The role of JNK in islet transplantation has also been investigated. Inhibition of JNK during human or pig islet isolation (53–55) and culture (54) improves transplantation outcome in a mouse model.

One reason for the differing results in vivo compared with in vitro could be that the in vitro environment does not reflect the stresses that islets face in the post-transplantation period. One important difference may be the levels of oxygen available, which has previously been implicated as an important factor in islet NF-κB activation in response to transplantation (49). Also it should be noted that only partial protection was seen in vitro, which may not be sufficient to change the outcome of transplantation. However, it is worth noting that, although not reaching statistical significance, in every experimental series the imatinib-treated islets performed marginally better than the control islets, which may be indicative of a subtle effect. This is similar to our previous study where inhibition of NF-κB in islets prior to implantation using salicylate had a subtle but non-significant effect (P < 0.072) (52). However, subtle effects mediated by other pathways such as JNK, ERK, beta-catenin, and PKCδ cannot be ruled out. We have previously noted that promising results in islets in vitro do not always lead to improved function after transplantation; for example, prevention of endothelial cell death in islets in vitro did not improve islet transplantation outcome (19). One factor which may be of importance is the ability of the protective compound to sustain beneficial effects after islet transplantation. Although imatinib seems to be able to protect islets in vitro after its removal, its ability to be effective in vivo may require further exposure. Indeed, when we administered imatinib to the mice immediately before and for 3 days after implantation a significant improvement was seen in blood glucose concentrations. However, this effect was lost by day three, which is evident by no difference in insulin content of the grafts upon removal.

We have previously improved islet transplantation outcome by pre-treating the islets in vitro with either cells (21,22) or compounds (24,56). Interestingly, these interventions, which have been successful, have all improved glucose-induced insulin secretion in the islets prior to transplantation. It is perhaps not surprising that implanting well-functioning islets may be the key to successful transplantation outcome.

Figure 3. Blood glucose concentrations of diabetic mice after transplantation of 200 islets pre-cultured with imatinib for 3 days (A) or 24 hours (B). Two-way rm ANOVA, effect of imatinib P = 0.356 (A), and P = 0.358 (B). Effect of time P < 0.05 in (A) and (B); n = 5 (A) and n = 5–7 (B).

Figure 4. A: Blood glucose concentrations of diabetic mice after transplantation of 200 control-cultured islets or 200 islets pre-cultured with imatinib for 24 hours combined with the recipient receiving imatinib by gavage. A separate group of non-transplanted animals received imatinib gavage. *P < 0.01 versus non-transplanted imatinib gavage; †P < 0.05 versus control-cultured islet graft. Two-way rm ANOVA, n = 6–7. B: Insulin content of islet grafts on day three after transplantation. P = 0.873, t test, n = 5–7.
The superior outcome of islet transplantation outcome when islets were only cultured for 1 day (Figures 3B and 4A) rather than 3 days (Figure 3A) may also reflect this point, with cultured islets losing beta cell mass. Although it has been well documented that inflammation around the time of transplantation leads to loss of a substantial amount of the islets (57,58), pre-treatment of islets against inflammation may not be sufficient to protect them against the harsh in vivo environment. We are therefore currently focusing on strategies that will deliver anti-inflammatory agents to the site of implantation. To do this we have applied a layer-by-layer nanoencapsulation method which can incorporate anti-inflammatory peptides such as α1-anti-trypsin (59). It is possible that this strategy combined with using insulinotropic peptides will lead to better function and survival of islets in a transplantation setting.

Disclosure statement

We are grateful to the Research Councils UK and British Pharmacological Society Integrative Pharmacology Fund for funding. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

1. Olerud J, Johansson M, Lawler J, Welsh N, Carlsson PO. Improved vascular engraftment and graft function after inhibition of the angiostatic factor thrombospondin-1 in mouse pancreatic islets. Diabetes. 2008;57:1870–7.
2. Olsson R, Carlsson PO. Better vascular engraftment and function in pancreatic islets transplanted without prior culture. Diabetologia. 2005;48:469–76.
3. Espes D, Lau J, Quach M, Banerjee U, Palmer AF, Carlsson PO. Cotransplantation of polymerized hemoglobin reduces beta-cell hypoxia and improves beta-cell function in intramuscular islet grafts. Transplantation. 2015;99:2077–82.
4. Lau J, Vasylovsksa S, Kozlova EN, Carlsson PO. Surface coating of pancreatic islets with neural crest stem cells improves engraftment and function after intratropical transplantation. Cell Transplant. 2015;24:2263–72.
5. Andersson A, Eizirik DL, Bremer C, Johnson RC, Pipeleers DG, Hellerstrom C. Structure and function of macroencapsulated human and rodent pancreatic islets transplanted into nude mice. Horm Metab Res. 1996;28:306–9.
6. Carlsson PO, Andersson A,Carlsson C, Hellerstrom C, Hoglund E, King A, et al. Engraftment and growth of transplanted pancreatic islets. Ups J Med Sci. 2000;105:107–23.
7. Eizirik DL, Jansson L, Flodstrom M, Hellerstrom C, Andersson A. Mechanisms of protective glucose-induced insulin release in human pancreatic islets transplanted to diabetic nude mice. J Clin Endocrinol Metab. 1997;82:2660–3.
8. Jansson L, Eizirik DL, Pipeleers DG, Borg LA, Hellerstrom C, Andersson A. Impairment of glucose-induced insulin secretion in human pancreatic islets transplanted to diabetic nude mice. J Clin Invest. 1995;96:721–6.
9. King A, Sandler S, Andersson A, Hellerstrom C, Kulseng B, Skjak-Braek G. Glucose metabolism in vitro of cultured and transplanted mouse pancreatic islets microencapsulated by means of a high-voltage electrostatic field. Diabetes Care. 1999;22(Suppl 2):B121–6.
10. Sandberg JO, Olsson N, Johnson RC, Hellerstrom C, Andersson A. Immunosuppression, macroencapsulation and ultraviolet-B irradiation as immunoprotection in porcine pancreatic islet xenotransplantation. Pharmacol Toxicol. 1995;76:400–5.
11. Sandler S, Andersson A, Eizirik DL, Hellerstrom C, Espevik T, Kulseng B, et al. Assessment of insulin secretion in vivo from microencapsulated fetal porcine islet-like cell clusters and rat, mouse, and human pancreatic islets. Transplantation. 1997;63:1712–18.
12. Tyberg B, Eizirik DL, Hellerstrom C, Pipeleers DG, Andersson A. Human pancreatic beta-cell deoxyribonucleic acid-synthesis in islet grafts decreases with increasing organ donor age but increases in response to glucose stimulation in vitro. Endocrinology. 1996;137:5694–9.
13. Westermark P, Eizirik DL, Pipeleers DG, Hellerstrom C, Andersson A. Rapid deposition of amyloid in human islets transplanted into nude mice. Diabetologia. 1995;38:543–9.
14. Bohman S, Andersson A, King A. No differences in efficacy between noncultured and cultured islets in reducing hyperglycemia in a nonvascularized islet graft model. Diabetes Technol Ther. 2006;8:536–45.
15. Bohman S, King AJ. Islet alpha cell number is maintained in microencapsulated islet transplantation. Biochim Biophys Res Commun. 2008;377:729–33.
16. Bohman S, Waern I, Andersson A, King A. Transient beneficial effects of exendin-4 treatment on the function of microencapsulated mouse pancreatic islets. Cell Transplant. 2007;16:15–22.
17. Kerby A, Bohman S, Westberg H, Jones P, King A. Immunosolation of islets in high gulosuronic acid barium-alginate microcapsules does not improve graft outcome at the subcutaneous site. Artif Organs. 2012;36:664–70.
18. Kerby A, Jones ES, Jones PM, King AJ. Co-transplantation of islets with mesenchymal stem cells in microcapsules demonstrates graft outcome can be improved in an isolated-graft model of islet transplantation in mice. Cytotherapy. 2013;15:192–200.
19. King AJ, Clarkin CE, Austin ALF, Ajram L, Dhunna JK, Jamil MO, et al. ALKS inhibition maintains islet endothelial cell survival but does not enhance islet graft revascularisation or function. Horm Metab Res. 2015;47:78–83.
20. Rackham CL, Chagastelles PC, Nardi NB, Hauge-Evans AC, Jones PM, King AJ. Co-transplantation of mesenchymal stem cells maintains islet organisation and morphology in mice. Diabetologia. 2011;54:1127–35.
21. Rackham CL, Dhadda PK, Le Lay AM, King AJF, Jones PM. Pre-culturing islets with adipose-derived mesenchymal stromal cells is an effective strategy for improving transplantation efficiency at the clinically-preferred intraportal site. Cell Med. 2014;73:47–77.
22. Rackham CL, Dhadda PK, Chagastelles PC, Simpson SJ, Dattani AA, Bowe JE, et al. Pre-culturing islets with mesenchymal stromal cells using a direct contact configuration is beneficial for transplantation outcome in diabetic mice. Cytotherapy. 2013;15:449–59.
23. Rackham CL, Jones PM, King AJ. Maintenance of islet morphology is beneficial for transplantation outcome in diabetic mice. PLoS One. 2013;8:e57844.
24. Rackham CL, Vargas AE, HawkES RG, Amisten S, Persaud SJ, Austin AL, et al. Annexin A1 is a key modulator of mesenchymal stromal cell mediated improvements in islet function. Diabetes. 2016;65:129–39.
25. Zhi Z, Kerby A, King AJF, Jones PM, Pickup JC. Nano-scale encapsulation enhances allograft survival and function of islets transplanted in a mouse model of diabetes. Diabetologia. 2012;55:1081–90.
26. Hellerstrom C, Howell SL, Edwards JC, Andersson A. An investiga-
tion of glucagon biosynthesis in isolated pancreatic islets of guinea pigs. FEBS Lett. 1972;27:97–101.
27. Rackham CL, Vargas AE, HawkES RG, Amisten S, Persaud SJ, Austin AL, et al. Annexin A1 is a key modulator of mesenchymal stromal cell mediated improvements in islet function. Diabetes. 2016;65:129–39.
28. Howell SL, Hellerstrom C, Tynhus M. Intracellular transport and storage of newly synthesised proteins in the guinea pig pancreatic A cell. Horm Metab Res. 1972;7:27–97.
29. Howell SL, Hellerstrom C, Whitfield M. Radioautographic localization of labelled proteins after incubation of guinea-pig islets of Langerhans with 3H-trytophan. Biochem J. 1974;140:22–3.
30. Howell SL, Tyhurst M, Duvefelt H, Andersson A, Hellerstrom C. Role of zinc and calcium in the formation and storage of insulin in the pancreatic beta-cell. Cell Tissue Res. 1978;188:107–18.

31. Swenne I, Bone AJ, Howell SL, Hellerstrom C. Effects of glucose and amino acids on the biosynthesis of DNA and insulin in fetal rat islets maintained in tissue culture. Diabetes. 1980;29:686–92.

32. Hagerkvist R, Jansson L, Welsh N. Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci (Lond). 2008;114:65–71.

33. Hagerkvist R, Makeeva N, Elliman S, Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J. 2007;21:618–28.

34. Mokhtari D, Al-Amin A, Turpaev K, Li T, Idevall-Hagren O, Li J, et al. Imatinib mesylate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphate interaction with c-Abl. Diabetologia. 2013;56:1327–38.

35. Mokhtari D, Li T, Lu T, Welsh N. Effects of imatinib mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro. PLoS One. 2011;6:e24831.

36. Mokhtari D, Welsh N. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond). 2010;118:241–7.

37. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100–4.

38. Raina D, Mishra N, Kumar S, Kharbanda S, Saxena S, Kufe D. Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine. Mol Pharmacol. 2002;61:1489–95.

39. Wang JY, Ki SW. Choosing between growth arrest and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine. Mol Pharmacol. 2002;61:1489–95.

40. Wang JY, Ki SW. Choosing between growth arrest and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine. Mol Pharmacol. 2002;61:1489–95.

41. Raina D, Pandey P, Ahmad R, Bharti A, Ren J, Kharbanda S, et al. c-Abl tyrosine kinase regulates caspase-9 autocleavage in the apoptotic response to DNA damage. J Biol Chem. 2005;280:11147–51.

42. Jones PM, Salmon DM, Howell SL. Protein phosphorylation in electrically permeabilized islets of Langerhans. Effects of Ca2+, cyclic AMP, a phorbol ester and noradrenaline. Biochem J. 1988;254:397–403.

43. Pan Y, Sun L, Wang J, Fu W, Fu Y, Wang J, et al. STI571 protects neuronal cells from neurotic proinflammatory fragment-induced apoptosis. Neuropsychopharmacology. 2015;39:191–8.

44. Kumar S, Mishra N, Raina D, Saxena S, Kufe D. Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571. Mol Pharmacol. 2003;63:276–82.

45. Karunakaran U, Park SJ, Jun do Y, Sim T, Park KG, Kim MO, et al. Non-receptor tyrosine kinase inhibitors enhances beta-cell survival by suppressing the PKCdelta signal transduction pathway in streptozotocin-induced beta-cell apoptosis. Cell Signal. 2015;27:1066–74.

46. Lau J, Zhou Q, Sutton SE, Herman AE, Schmedt C, Glynne R. Inhibition of c-Kit is not required for reversal of hyperglycemia by imatinib in NOD mice. PLoS One. 2014;9:e84900.

47. Fountas A, Diamantopoulos LN, Tsatsoulis A. Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm? Trends Endocrinol Metab. 2015;26:433–56.

48. Fred RG, Boddeki SK, Lundberg M, Welsh N. Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells. Clin Sci (Lond). 2015;128:17–28.

49. Chen C, Moreno R, Samikannu B, Bretzel RG, Schmitz ML, Linn T. Improved intraportal islet transplantation outcome by systemic IKK-beta inhibition: NF-kappaB activity in pancreatic islets depends on oxygen availability. Am J Transplant. 2011;11:215–24.

50. Rink JS, Chen X, Zhang X, Kaufman DB. Conditional and specific inhibition of NF-kappaB in mouse pancreatic beta cells prevents cytokine-induced deleterious effects and improves islet survival posttransplant. Surgery. 2012;151:330–9.

51. Takahashi T, Matsumoto S, Matsuhashi M, Kamachi H, Tsuruga Y, Kashi H, et al. Donor pretreatment with DHMEQ improves islet transplantation. J Surg Res. 2010;163:e23–34.

52. King AJ, Guo Y, Cai D, Hollister-Lock J, Morris B, Salvatori A, et al. Sustained NF-kappaB activation and inhibition in beta-cells have minimal effects on function and islet transplant outcomes. PLoS One. 2013;8:e74452.

53. Bogu H, Matsumoto S, Onaka N, Naziruddin B, Jackson A, Ikemoto T, et al. Ductal injection of JNK inhibitors before pancreas preservation prevents islet apoptosis and improves islet graft function. Hum Gene Ther. 2009;20:73–85.

54. Bogu H, Nakay M, Matsumoto S, Kawaguchi M, Ueda M, Okitsu T, et al. Cell permeable peptide of JNK inhibitor prevents islet apoptosis immediately after isolation and improves islet graft function. Am J Transplant. 2005;5:1848–55.

55. Jin SM, Kim KS, Lee SY, Gong CH, Park SK, Shin JS, et al. The sequential combination of a JNK inhibitor and simvastatin protects porcine islets from peritransplant apoptosis and inflammation. Cell Transplant. 2011;20:1139–51.

56. King A, Lock J, Xu G, Bonner-Weir S, Weir GC. Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment. Diabetologia. 2005;48:2074–79.

57. Barshees NR, Wylle S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J Leukoc Biol. 2005;77:587–97.

58. Eriksson O, Alavi A. Imaging the islet graft by positron emission tomography. Eur J Nucl Med Mol Imaging. 2012;39:533–42.

59. Zhi ZL, Singh J, Austin AL, Hope DC, King AJ, Persaud SJ, et al. Assembly of bioactive multilayered nanocoatings on pancreatic islet cells: incorporation of alpha1-antitrypsin into the coatings. Chem Commun (Camb). 2015;51:10652–5.